Efficacy and Tolerability of the Association of Sibutramine and Orlistat for Six Months in Overweight and Obese Patients

Halpern, Alfredo; Pepe, Renata B.; Monegaglia, Ana Paola; Beyruti, Monica; Melo, Maria Edna de; Mancini, Márcio C.

doi:10.1155/2010/602537

Cited by 7 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The principles and behaviour methods of this weight reduction programme are described elsewhere [14]. All participants attended bimonthly consultations in the asthma clinic, where they were seen by the same investigator (S.A. Dias-Jú nior), had the use of their inhaler checked, compliance with medication assessed by a count of the remaining doses, received the same amount of education about asthma [15], and were followed for 6 months.…”

Section: Design Overviewmentioning

confidence: 99%

Effects of weight loss on asthma control in obese patients with severe asthma

Dias-Júnior

Reis

Carvalho-Pinto

et al. 2013

European Respiratory Journal

148

View full text Add to dashboard Cite

Studies on the effects of weight loss in patients with asthma are scarce. No studies have been performed in patients with severe asthma. Therefore, the aim of the present study was to assess the impact of weight loss in patients with severe asthma associated with obesity.This was an open, prospective, randomised study of two parallel groups, in patients with severe uncontrolled asthma and moderate obesity. The primary outcome was the level of asthma control 6 months after initiation of the weight reduction programme, quantified using the Asthma Control Questionnaire (ACQ). We evaluated clinical parameters, lung function, markers of airway inflammation and circulating cytokines.22 patients were randomised to undergo treatment for obesity and 11 to the control group. The weight reduction programme was associated with significant improvements in asthma control (mean¡SE ACQ score 3.02¡0.19 to 2.25¡0.28 in the treatment group versus 2.91¡0.25 to 2.90¡0.16 in the controls, p50.001). This improvement was not accompanied by changes in markers of airway inflammation or bronchial reactivity, but by an increase in forced vital capacity.Our results suggest that weight reduction in obese patients with severe asthma improves asthma outcomes by mechanisms not related to airway inflammation. @ERSpublications Weight loss improves outcomes in severely asthmatic obese patients; poor control results from obesity-related factors

show abstract

Section: Design Overviewmentioning

confidence: 99%

Effects of weight loss on asthma control in obese patients with severe asthma

Dias-Júnior

Reis

Carvalho-Pinto

et al. 2013

European Respiratory Journal

148

View full text Add to dashboard Cite

show abstract

“…Phentermine is contraindicated in severe hypertension, cardiac disease, glaucoma, history of drug abuse, and past antidepressants use. 31 Orlistat is contraindicated in gastrointestinal problems, 32 anorexia, pregnancy, and vitamin deficiency. 33 Liraglutide is contraindicated in history of pancreatitis or medullary cell thyroid and cancer.…”

Section: Discussionmentioning

confidence: 99%

Pharmacological Treatment for Obesity in Adults: An Umbrella Review

et al. 2020

View full text Add to dashboard Cite

Objective: To synthesize the evidence from systematic reviews of clinical trials investigating the effectiveness of pharmacological therapies approved by the Australian Therapeutic Goods Administration and the US Food and Drug Administration for the management of obesity in adults. Data Sources: A 3-step literature search of the MEDLINE, EMBASE, CINAHL, and PubMed databases was conducted between March and May 2019. The key terms used were obesity, pharmacological therapy, antiobesity agent, antiobesity medication, weight loss, and systematic review. Study Selection and Data Extraction: Systematic reviews that evaluated the effectiveness of pharmacological therapies for the management of obesity in patients with a body mass index of or greater than 25 kg/m2. Data Synthesis: Nine systematic reviews involving three pharmacotherapies, liraglutide, orlistat, and naltrexone-bupropion were identified. The results indicate that the pharmacotherapies reduced weight when compared with placebo. Orlistat was effective in significantly reducing fasting blood glucose, HbA1c, total cholesterol, triglycerides, and systolic and diastolic blood pressure. All reviews discussed the presence or risk of gastrointestinal adverse effects including diarrhea, vomiting, and nausea related to orlistat and liraglutide. Relevance to Patient Care and Clinical Practice: This umbrella review compares the efficacy and safety of antiobesity medications for reducing weight and a discussion on their weight loss and metabolic control to guide clinicians when prescribing medications for obesity. Conclusions: All pharmacological therapies included in this review are superior to placebo in reducing weight. Clinicians should consider patient comorbidities and risk of adverse events when recommending medications for weight loss.

show abstract

“…A large clinical series done by our group was developed to evaluate the efficacy of the combination of sibutramine and orlistat in 446 individuals for six months, with concomitant dietary counseling [ 10 ]. Weight loss in three and six months was 9.9 and 13.4% for women and 8.7 and 12.3% for men.…”

Section: Combinations Currently In Use and Being Studiedmentioning

confidence: 99%

“…Considering that obesity is a multifactorial disease, with environmental factors linked to genetic factors, it is expected that drug monotherapy may result in unsatisfactory outcomes. In analogy to the treatment of hypertension, where a combination of antihypertensive agents with different mechanisms of action is widely used to control blood pressure, obesity treatment using combinations of medications, working synergistically or in parallel [ 10 ], can result in a higher chance of weight loss and a reduction in the dropout rates.…”

Section: Introductionmentioning

confidence: 99%

Combinations of drugs in the Treatment of Obesity

et al. 2010

Self Cite

View full text Add to dashboard Cite

Obesity is a chronic disease associated with excess morbidity and mortality. Clinical treatment, however, currently offers disappointing results, with very high rates of weight loss failure or weight regain cycles, and only two drugs (orlistat and sibutramine) approved for long-term use. Drugs combinations can be an option for its treatment but, although widely used in clinical practice, very few data are available in literature for its validation. Our review focuses on the rationale for their use, with advantages and disadvantages; on combinations often used, with or without studies; and on new perspectives of combinations being studied mainly by the pharmaceutical industry.

show abstract

Efficacy and Tolerability of the Association of Sibutramine and Orlistat for Six Months in Overweight and Obese Patients

Cited by 7 publications

References 14 publications

Effects of weight loss on asthma control in obese patients with severe asthma

Effects of weight loss on asthma control in obese patients with severe asthma

Pharmacological Treatment for Obesity in Adults: An Umbrella Review

Combinations of drugs in the Treatment of Obesity

Contact Info

Product

Resources

About